Needham & Company Starts Agios Pharma (AGIO) at Buy

Needham & Company initiates coverage on Agios Pharma (NASDAQ: AGIO) with a Buy rating and a price target of $60.00.

Analyst Chad Messer commented, "Agios develops novel therapies to correct errors in cellular metabolism that occur in cancer and rare genetic disorders. The company is running clinical programs in two major areas: 1) isocitrate dehydrogenase (IDH) inhibition in oncology; and 2) pyruvate kinase (PK) activation for an orphan metabolic disorder. Both programs have demonstrated clinical proof of concept, and two mutant IDH inhibitors (AG-221 and AG-120) are on the verge of entering pivotal studies in record time. We believe targeting mutant IDH represents a fundamentally different mechanistic approach to fighting cancer. The company also has a high-profile partnership with Celgene, providing financial resources and validation."

For an analyst ratings summary and ratings history on Agios Pharma click here. For more ratings news on Agios Pharma click here.

Shares of Agios Pharma closed at $49.12 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• Owens Corning (OC) PT Raised to $172 at Evercore ISI
• Compass Minerals International (CMP) PT Lowered to $15 at Deutsche Bank